Inside informationEnglish
CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam)
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Crossject
- Filed
- 22/09/2025, 07:30
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 119053_20250922